GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-05-17| Licensing

AbbVie & Cugene Join Forces to Tackle Autoimmune Diseases

by Fujie Tham
Share To

US Chicago-based AbbVie and Waltham, Massachusetts’ Cugene inked a deal for developing autoimmune diseases and cancer treatments. The pact focuses on a worldwide license option agreement for a potential best-in-class Treg-selective IL-2 mutein (CUG252) in addition to other novel IL-2 muteins.

Cugene’s lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive regulatory T (Treg) cells while reducing undesired IL-2 activity on other IL-2 receptor cells for the treating autoimmune diseases. Currently, CUG252 is in a Phase 1 study involving healthy volunteers.

Autoimmune diseases occur when the body’s immune system cannot differentiate the body’s cells and foreign cells, causing the body to mistakenly attack normal cells. CUG252 focuses on IL-2 (interleukin-2), which controls the homeostasis and function of Treg cells, and defects in the IL-2 pathway contribute to various autoimmune disorders. Therefore, IL-2’s pro- and anti-inflammatory functions make it an attractive candidate for immunotherapy.

Related article: The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products

 

AbbVie’s Dominance in Immunotherapy

 

Abbvie’s rheumatoid arthritis drug – Humira, has been the brand’s best-selling monoclonal antibody drug since marketing. However, facing increased biosimilars competition, Humira’s net revenue hit a 23% decrease in Q1 2022, again signaling the company to diversify/adapt its products, with new lineups such as Skyrizi and Rinvoq for rheumatoid arthritis.

AbbVie is joining an increasingly saturated Treg space filled by Eli Lilly, Merck, Takeda, and booming biotech startups. It is paying Cugene $48.5 Million upfront, betting on its selective IL-2 muteins’ potential to be a major advancement for patients with autoimmune and inflammatory illnesses. Under the terms of the agreement, AbbVie will receive an option to obtain an exclusive license for certain IL-2 muteins including CUG252, while Cugene will conduct a Phase 1b study in patients with autoimmune/inflammatory diseases. Upon exercise of the option, AbbVie will conduct all future clinical development, manufacturing, and marketing activities for CUG252.

Related article: The Next SuperStar Drug? AbbVie Places its Hope on Skyrizi and Rinvoq

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Ipsen Bets $600M on Biomunex’s First-in-Class T-Cell Engager BMX-502
2024-12-03
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top